Enhancing the Utility of the Trend-in-Trend Research Design

增强趋势研究设计的实用性

基本信息

  • 批准号:
    10017817
  • 负责人:
  • 金额:
    $ 54.92万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-09-15 至 2023-05-31
  • 项目状态:
    已结题

项目摘要

Patients, clinicians, and policymakers often need valid information about the real-world effects of drugs and other exposures for which there have been pronounced time-trends in use. For example, the rapid growth in the use of rofecoxib in the early 2000s and of exogenous testosterone from 2000–2013 was accompanied by an urgent need for knowledge about the cardiovascular effects of those drugs. Randomized trials seldom enroll a sufficient number of subjects, or follow them long enough, to examine associations with rare outcomes. Therefore, non-randomized studies are needed, even though they are susceptible to unmeasured confounding and other forms of bias. To address these limitations of available epidemiologic designs, we recently introduced the trend-in-trend design: a novel, hybrid epidemiologic-ecologic research design that is applicable when there is a prominent trend in the use of the study exposure. Substantial additional development is needed to realize the full public health impact of the trend-in-trend research design. Areas in most need of development include: evaluation of a sequential analysis extension for real-time post-marketing safety surveillance; evaluation of machine learning to specify the trend-in-trend design’s underlying cumulative probability of exposure model; evaluation of dose-response relationships; and evaluation of treatment effect heterogeneity based on baseline patient characteristics. For each of these methodologic needs, we propose an approach for which we will: 1) assess its statistical properties, in particular large-sample validity through asymptotics and finite sample statistical power; 2) evaluate its performance in thorough simulation studies; and 3) proof-test the approach using the known association between rofecoxib-acute myocardial infarction in healthcare data. Finally, we will apply these developments to the unresolved and highly important question of the cardiovascular, cerebrovascular, and thromboembolic effects of exogenous testosterone in men. This study will have broad scientific, clinical, and public health impact by greatly extending the utility of a novel epidemiologic research design with demonstrated validity and is applicable to a broad range of exposures with a prominent trend in use. It will also evaluate the safety of exogenous testosterone, a question of tremendous clinical and public health importance. Examining the safety of prescription drugs is one enormously important application of this design that has the potential to benefit many millions of people. As the trend-in-trend design is also applicable to non-drug exposures that have a pronounced time-trend (e.g., medical procedures, lifestyle factors, environmental exposures, etc.), its potential impact on the population is even broader.
患者、临床医生和政策制定者通常需要关于药物和其他药物的真实效果的有效信息 曝光有明显的时间-使用趋势。例如,罗非昔布的使用量迅速增长 21世纪初和2000-2013年外源性睾丸素的增加伴随着对知识的迫切需求 关于这些药物对心血管的影响。随机试验很少招募足够数量的受试者,或跟随 足够长的时间,以检查与罕见结果的关联。因此,需要进行非随机研究,甚至 尽管他们很容易受到无法测量的混杂和其他形式的偏见的影响。要解决这些可用的限制, 流行病学设计,我们最近引入了趋势设计:一种新的、混合的流行病学-生态研究 适用于设计时有突出使用趋势的书房曝光。大幅增加 需要发展,以实现趋势研究设计对公众健康的全面影响。最需要的领域 发展包括:评估用于实时上市后安全监测的序贯分析扩展; 对机器学习的评估,以确定趋势设计的潜在累积曝光概率 模型;剂量-反应关系的评估;以及基于基线的治疗效果异质性评估 病人的特征。对于这些方法论需求中的每一种,我们都会提出一种方法:1)评估其 统计性质,特别是通过渐近性和有限样本统计能力的大样本有效性;2) 评估其在深入的模拟研究中的性能;以及3)使用已知的关联来验证该方法 罗非昔布-急性心肌梗死之间的医疗保健数据。最后,我们将把这些发展应用于 心血管、脑血管和血栓栓塞症的影响这一悬而未决的重要问题 男性体内的外源性睾丸素。 这项研究将通过极大地扩展一种新的实用程序,对科学、临床和公共卫生产生广泛的影响 流行病学研究设计,具有证明的有效性,适用于广泛的暴露和 使用趋势突出。它还将评估外源性睾丸素的安全性,这是一个巨大的临床和 公共卫生的重要性。检查处方药的安全性是这一方法的一个极其重要的应用 有可能造福数百万人的设计。由于趋势设计也适用于非药物 具有明显时间趋势的暴露(例如,医疗程序、生活方式因素、环境暴露等); 它对人口的潜在影响甚至更广泛。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sean Hennessy其他文献

Sean Hennessy的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sean Hennessy', 18)}}的其他基金

Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest
涉及第二代抗精神病药物的药物相互作用导致心脏骤停
  • 批准号:
    10661090
  • 财政年份:
    2022
  • 资助金额:
    $ 54.92万
  • 项目类别:
Drug Interactions Involving Second-generation Antipsychotic Agents Leading to Sudden Cardiac Arrest
涉及第二代抗精神病药物的药物相互作用导致心脏骤停
  • 批准号:
    10501196
  • 财政年份:
    2022
  • 资助金额:
    $ 54.92万
  • 项目类别:
Stimulant Overdose in the Medicaid Population: Who is at Risk, and When are They at Risk
医疗补助人群中兴奋剂过量:谁有风险,何时有风险
  • 批准号:
    10662407
  • 财政年份:
    2021
  • 资助金额:
    $ 54.92万
  • 项目类别:
Stimulant Overdose in the Medicaid Population: Who is at Risk, and When are They at Risk
医疗补助人群中兴奋剂过量:谁有风险,何时有风险
  • 批准号:
    10392130
  • 财政年份:
    2021
  • 资助金额:
    $ 54.92万
  • 项目类别:
Drug-Drug Interactions Involving Methadone and Buprenorphine
涉及美沙酮和丁丙诺啡的药物相互作用
  • 批准号:
    10436942
  • 财政年份:
    2019
  • 资助金额:
    $ 54.92万
  • 项目类别:
Drug-Drug Interactions Involving Methadone and Buprenorphine
涉及美沙酮和丁丙诺啡的药物相互作用
  • 批准号:
    10205012
  • 财政年份:
    2019
  • 资助金额:
    $ 54.92万
  • 项目类别:
Drug-Drug Interactions Involving Methadone and Buprenorphine
涉及美沙酮和丁丙诺啡的药物相互作用
  • 批准号:
    10649570
  • 财政年份:
    2019
  • 资助金额:
    $ 54.92万
  • 项目类别:
Enhancing the Utility of the Trend-in-Trend Research Design
增强趋势研究设计的实用性
  • 批准号:
    9813026
  • 财政年份:
    2019
  • 资助金额:
    $ 54.92万
  • 项目类别:
Enhancing the Utility of the Trend-in-Trend Research Design
增强趋势研究设计的实用性
  • 批准号:
    10162467
  • 财政年份:
    2019
  • 资助金额:
    $ 54.92万
  • 项目类别:
Drug-Drug Interactions Involving Antidiabetic Agents
涉及抗糖尿病药物的药物相互作用
  • 批准号:
    9282425
  • 财政年份:
    2014
  • 资助金额:
    $ 54.92万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 54.92万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 54.92万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.92万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.92万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 54.92万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.92万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 54.92万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 54.92万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 54.92万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 54.92万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了